Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shared First Interchangeable Biosimilar Exclusivity May Be Allowed Under US FDA User Fee Bill

Executive Summary

Legislation in development also could create an option for tentative approval of interchangeable biosimilars.

You may also be interested in...



Pfizer Anticipates ‘Fair’ Share Of Adalimumab Market In US

Pfizer expects to make significant strides in the adalimumab market once it launches its Humira biosimilar late next year, but may not be able to enjoy its anticipated interchangeability designation until 2024.

US FDA Orphan Exclusivity Would Revert To Pre-Catalyst Status Under Senate Legislation

Federal court decision said the FDA cannot grant orphan exclusivity for subpopulations of a disease, which agency officials fear could damage pediatric rare disease drug development.

Complete Response Letters: Industry Prefers Communication Before Rather Than Docs After

Rep. Dunn’s idea would be a return to prior agency practice; the documents are currently considered exempt from disclosure.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151847

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel